D-泛硫乙胺
D-泛硫乙胺结构式
|
常用名 | D-泛硫乙胺 | 英文名 | D-pantethine anhydrous |
|---|---|---|---|---|
| CAS号 | 16816-67-4 | 分子量 | 554.72100 | |
| 密度 | 1.277g/cm3 | 沸点 | 987.2ºC at 760mmHg | |
| 分子式 | C22H42N4O8S2 | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | 550.8ºC |
|
Variation in pantothenate kinase type determines the pantothenamide mode of action and impacts on coenzyme A salvage biosynthesis.
FEBS J. 281(20) , 4731-53, (2014) N-substituted pantothenamides are analogues of pantothenic acid, the vitamin precursor of CoA, and constitute a class of well-studied bacterial growth inhibitors that show potential as new antibacterial agents. Previous studies have highlighted the importance... |
|
|
Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model.
Brain 137(Pt 1) , 57-68, (2014) Pantothenate kinase-associated neurodegeneration, caused by mutations in the PANK2 gene, is an autosomal recessive disorder characterized by dystonia, dysarthria, rigidity, pigmentary retinal degeneration and brain iron accumulation. PANK2 encodes the mitocho... |
|
|
Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury.
BMC Neurosci. 11 , 51, (2010) The administration of the ketone bodies hydroxybutyrate and acetoacetate is known to exert a protective effect against metabolic disorders associated with cerebral pathologies. This suggests that the enhancement of their endogenous production might be a ratio... |
|
|
The STM4195 gene product (PanS) transports coenzyme A precursors in Salmonella enterica.
J. Bacteriol. 197(8) , 1368-77, (2015) Coenzyme A (CoA) is a ubiquitous coenzyme involved in fundamental metabolic processes. CoA is synthesized from pantothenic acid by a pathway that is largely conserved among bacteria and eukaryotes and consists of five enzymatic steps. While higher organisms, ... |
|
|
Can drugs or micronutrients prevent cataract?
Drugs Aging 18(7) , 473-86, (2001) Cataract is the major cause of blindness and of visual impairment worldwide, so its prevention is of the greatest importance. At present no drug therapy is licensed for use in the UK or the US, so the only treatment for cataract is by surgery, which is expens... |
|
|
Physiological and performance responses to supplementation with thiamin and pantothenic acid derivatives.
Eur. J. Appl. Physiol. Occup. Physiol. 77(6) , 486-91, (1998) The purpose of this study was to investigate the physiological and performance responses to supplementation with allithiamin and pantethine. On two separate occasions, six highly trained cyclists [maximum O2 consumption or VO2max 61.8 (2.1) ml x kg(-1) x min(... |
|
|
Pantethine rescues phosphopantothenoylcysteine synthetase and phosphopantothenoylcysteine decarboxylase deficiency in Escherichia coli but not in Pseudomonas aeruginosa.
J. Bacteriol. 193(13) , 3304-12, (2011) Coenzyme A (CoA) plays a central and essential role in all living organisms. The pathway leading to CoA biosynthesis has been considered an attractive target for developing new antimicrobial agents with novel mechanisms of action. By using an arabinose-regula... |
|
|
Pantethine inhibits the formation of high-Tc protein aggregates in gamma B crystallin solutions.
Curr. Eye Res. 15(12) , 1182-90, (1996) Solutions of the bovine lens protein gamma B (or gamma II) crystallin at neutral pH in the absence of reducing agents, undergo a slow, partial conversion to a new protein species, gamma IIH. This species is an aggregate composed of an intermolecular, disulfid... |
|
|
The role of nutraceutical supplements in the treatment of dyslipidemia.
J. Clin. Hypertens. (Greenwich.) 14(2) , 121-32, (2012) The combination of a lipid-lowering diet and scientifically proven nutraceutical supplements has the ability to significantly reduce low-density lipoprotein (LDL) cholesterol, increase LDL particle size, decrease LDL particle number, lower trigylcerides and v... |
|
|
Reduction of pantethine in rabbit ocular lens homogenate.
J. Pharm. Biomed. Anal. 15(5) , 653-62, (1997) In several animal models, preliminary studies have indicated that pantethine may inhibit cataract formation. Therefore, preclinical trials need to be conducted to study the pharmacology of pantethine in the ocular lens and to establish its efficacy. Since pan... |